Gerd Kvale

Gerd Kvale

Auto-generated profile, based on publicly available information

Gerd Kvale

Bergen Center for Brain Plasticity, Haukeland University Hospital

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2018 in Cognitive Behaviour Therapy
Verified
Journal Article
Open access
BHBjarne Hansen
Bjarne Hansen
GKGerd Kvale
Gerd Kvale
KHKristen Hagen
Kristen Hagen
AHAudun Havnen
Audun Havnen
LÖLars-Göran Öst
Lars-Göran Öst
There are few long-term follow-up studies on psychological treatment of anxiety disorders carried out in clinical mental health settings, so called effectiveness studies. The present paper presents a four year follow-up of patients with obsessive-compulsive disorder treated by the Bergen 4-day treatment (B4DT), a concentrated form of exposure and response prevention (ERP). A total of 77 obsessive–compulsive disorder (OCD) patients received treatment during four consecutive days and were assessed with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) pre, post, and at follow-ups after 3 and 6 months, and 4 years post-treatment. The Y-BOCS mean score changed from 25.9 at pre- to 10.0 post-treatment and 9.9 at long-term follow-up. The proportion fulfilling the strict international consensus criteria for remission was 73% at post-treatment and 69% at follow-up. When taking declining rate, attrition rate, remission, relapse, and further improvement during the follow-up period into account, 72% were recovered on a long-term basis. A comparison with previously published effectiveness studies of ERP indicated that the 4-day treatment yielded significantly higher proportions of remission at post-treatment and recovery at follow-up, as well as within-group effect size on the Y-BOCS. The implications of these results are discussed.

2 May 2023 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
WBWillem B. Bruin
Willem B. Bruin
YAYoshinari Abe
Yoshinari Abe
PAPino Alonso
Pino Alonso
AAAlan Anticevic
Alan Anticevic
LBLea L. Backhausen
Lea L. Backhausen
DSDan J. Stein
Dan J. Stein
Current knowledge about functional connectivity in obsessive-compulsive disorder (OCD) is based on small-scale studies, limiting the generalizability of results. Moreover, the majority of studies have focused only on predefined regions or functional networks rather than connectivity throughout the entire brain. Here, we investigated differences in resting-state functional connectivity between OCD patients and healthy controls (HC) using mega-analysis of data from 1024 OCD patients and 1028 HC from 28 independent samples of the ENIGMA-OCD consortium. We assessed group differences in whole-brain functional connectivity at both the regional and network level, and investigated whether functional connectivity could serve as biomarker to identify patient status at the individual level using machine learning analysis. The mega-analyses revealed widespread abnormalities in functional connectivity in OCD, with global hypo-connectivity (Cohen’s d: -0.27 to -0.13) and few hyper-connections, mainly with the thalamus (Cohen’s d: 0.19 to 0.22). Most hypo-connections were located within the sensorimotor network and no fronto-striatal abnormalities were found. Overall, classification performances were poor, with area-under-the-receiver-operating-characteristic curve (AUC) scores ranging between 0.567 and 0.673, with better classification for medicated (AUC = 0.702) than unmedicated (AUC = 0.608) patients versus healthy controls. These findings provide partial support for existing pathophysiological models of OCD and highlight the important role of the sensorimotor network in OCD. However, resting-state connectivity does not so far provide an accurate biomarker for identifying patients at the individual level.

2 August 2022 in Behaviour Research and Therapy
Verified
Journal Article
Open access
LÖLars-Göran Öst
Lars-Göran Öst
PEPia Enebrink
Pia Enebrink
AFAnna Finnes
Anna Finnes
Ata GhaderiAta Ghaderi
Ata Ghaderi
AHAudun Havnen
Audun Havnen
GWGro Janne Wergeland
Gro Janne Wergeland
Cognitive behavioral therapy (CBT) has strong research support for obsessive-compulsive disorder (OCD). However, less is known about how CBT performs when delivered in routine clinical care. A systematic review and meta-analysis was conducted of CBT for OCD in adults treated in routine clinical care. Ovid MEDLINE, Embase OVID, and PsycINFO were systematically searched for studies published until July 2021. The effectiveness of CBT, methodological quality, and moderators of treatment outcome were examined, and benchmarked by meta-analytically comparing with efficacy studies for OCD. Twenty-nine studies (8 randomized controlled trials) were included, comprising 1669 participants. Very large within-group effect sizes (ES) were obtained for OCD-severity at post-treatment (2.12), and follow-up (2.30), on average 15 months post-treatment. Remission rates were 59.2% post-treatment and 57.0% at follow-up. Attrition rate was 15.2%. Risk of bias was considerable in the majority of studies. The benchmarking analysis showed that effectiveness studies had almost exactly the same ES as efficacy studies at post-treatment and somewhat higher at follow-up. Furthermore, effectiveness studies had significantly higher remission rates than efficacy studies, both at post- and follow-up assessment. CBT for OCD is an effective treatment when delivered in routine clinical care, with ES comparable to those found in efficacy studies. However, the evidence needs to be interpreted with caution because of the risk of bias in a high proportion of studies. PROSPERO REGISTRATION ID: CRD42021228828.

4 October 2018 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
GKGerd Kvale
Gerd Kvale
BHBjarne Hansen
Bjarne Hansen
TBThröstur Björgvinsson
Thröstur Björgvinsson
TBTore Børtveit
Tore Børtveit
KHKristen Hagen
Kristen Hagen
LÖLars-Göran Öst
Lars-Göran Öst
Oslo University Hospital, Norway, had by autumn 2016, accumulated a waiting list of 101 patients with obsessive-compulsive disorder (OCD) who had a legal right to receive treatment by a specialized OCD team. In this challenging situation, the Bergen OCD-team suggested to solve the problem by offering all patients an option for the rapid Bergen 4-day treatment (B4DT). The B4DT is an individual treatment delivered during four consecutive days in a group of six patients with the same number of therapists. The approach has previously shown a post-treatment response rate of 90% and a 3-month remission rate of 70%. Ninety-seven of the wait-list patients were available for the scheduled time slots, and 90 received the 4-day format during 8 days (45 patients each week). The therapists were recruited from 22 different specialized OCD-teams from all over Norway, and 44 (68%) had not previously delivered the 4-day format. Post-treatment; 91.1% of the patients were classified as responders, and 72.2% were in remission. At 3-month follow-up; 84.4 were classified as responders and the remission rate was 67.7%. Oslo University Hospital now offers the 4-day treatment as standard treatment for OCD. We conclude that the B4DT is an acceptable and potentially effective OCD-treatment.

9 June 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BFBente Frisk
Bente Frisk
MJMarte Jürgensen
Marte Jürgensen
BEBirgitte Espehaug
Birgitte Espehaug
KNKiri Lovise Njøten
Kiri Lovise Njøten
ESEirik Søfteland
Eirik Søfteland
GKGerd Kvale
Gerd Kvale
At least 65 million people suffer from long COVID. Treatment guidelines are unclear, especially pertaining to recommendations of increased activity. This longitudinal study evaluated safety, changes in functional level and sick leave following a concentrated rehabilitation program for patients with long COVID. Seventy-eight patients (19–67 years) participated in a 3-day micro-choice based rehabilitation program with 7-day and 3-month follow-up. Fatigue, functional levels, sick leave, dyspnea and exercise capacity were assessed. No adverse events were reported and 97.4% completed the rehabilitation. Fatigue measured with Chalder Fatigue Questionnaire decreased at 7-days [mean difference (MD = − 4.5, 95% CI − 5.5 to − 3.4) and 3-month (MD = − 5.5, 95% CI − 6.7 to − 4.3). Sick leave rates and dyspnea were reduced (p < 0.001) and exercise capacity and functional level increased (p < 0.001) at 3-month follow-up regardless of severity of fatigue at baseline. Micro-choice based concentrated rehabilitation for patients with long COVID was safe, highly acceptable and showed rapid improvements in fatigue and functional levels, sustaining over time. Even though this is a quasi-experimental study, the findings are of importance addressing the tremendous challenges of disability due to long COVID. Our results are also highly relevant for patients, as they provide the base for an optimistic outlook and evidence supported reason for hope.

3 August 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
GKGerd Kvale
Gerd Kvale
BHBjarne Hansen
Bjarne Hansen
KHKristen Hagen
Kristen Hagen
JAJonathan S. Abramowitz
Jonathan S. Abramowitz
TBTore Børtveit
Tore Børtveit
LÖLars-Göran Öst
Lars-Göran Öst
Obsessive-compulsive disorder (OCD) is a debilitating psychiatric disorder with a lifetime prevalence of 1% to 2%,1,2 often with onset in childhood.3 Exposure and response prevention (ERP) and antidepressants are effective treatments,4,5 but response is mixed, indicating a need to develop more effective strategies. Based on experimental animal studies demonstrating that D-cycloserine (DCS), a partial N-methyl-D-aspartate receptor agonist,6,7 facilitates extinction learning, a number of human clinical trials have assessed whether ERP is augmented by DCS. While some early publications were promising,8,9 more recent meta-analyses show only small augmentation of DCS vs placebo (effect size, 0.25)10 and others no significant difference,11-13 including no significant difference in several studies involving patients with OCD.10,11,14-16 A study by Andersson et al17 concluded that DCS did not augment the effects of cognitive behavioral therapy, but found that antidepressants may interact with DCS to block its facilitating effect on fear extinction.